Int. J. Mol. Sci. 2013, 14(1), 547-562; doi:10.3390/ijms14010547

Dendritic Cells and Multiple Sclerosis: Disease, Tolerance and Therapy

1,†email, 1,†email, 1email, 1email, 2email, 3email, 4email, 5email, 1email, 6email, 1email and 1,* email
Received: 25 September 2012; in revised form: 6 December 2012 / Accepted: 20 December 2012 / Published: 27 December 2012
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Multiple sclerosis (MS) is a devastating neurological disease that predominantly affects young adults resulting in severe personal and economic impact. The majority of therapies for this disease were developed in, or are beneficial in experimental autoimmune encephalomyelitis (EAE), the animal model of MS. While known to target adaptive anti-CNS immune responses, they also target, the innate immune arm. This mini-review focuses on the role of dendritic cells (DCs), the professional antigen presenting cells of the innate immune system. The evidence for a role for DCs in the appropriate regulation of anti-CNS autoimmune responses and their role in MS disease susceptibility and possible therapeutic utility are discussed. Additionally, the current controversy regarding the evidence for the presence of functional DCs in the normal CNS is reviewed. Furthermore, the role of CNS DCs and potential routes of their intercourse between the CNS and cervical lymph nodes are considered. Finally, the future role that this nexus between the CNS and the cervical lymph nodes might play in site directed molecular and cellular therapy for MS is outlined.
Keywords: multiple sclerosis; dendritic cell; experimental autoimmune encephalomyelitis; cervical lymph node; molecular therapy; cellular therapy; site directed local therapy
PDF Full-text Download PDF Full-Text [321 KB, Updated Version, uploaded 19 June 2014 04:36 CEST]
The original version is still available [189 KB, uploaded 19 June 2014 04:37 CEST]

Export to BibTeX |

MDPI and ACS Style

Mohammad, M.G.; Hassanpour, M.; Tsai, V.W.W.; Li, H.; Ruitenberg, M.J.; Booth, D.R.; Serrats, J.; Hart, P.H.; Symonds, G.P.; Sawchenko, P.E.; Breit, S.N.; Brown, D.A. Dendritic Cells and Multiple Sclerosis: Disease, Tolerance and Therapy. Int. J. Mol. Sci. 2013, 14, 547-562.

AMA Style

Mohammad MG, Hassanpour M, Tsai VWW, Li H, Ruitenberg MJ, Booth DR, Serrats J, Hart PH, Symonds GP, Sawchenko PE, Breit SN, Brown DA. Dendritic Cells and Multiple Sclerosis: Disease, Tolerance and Therapy. International Journal of Molecular Sciences. 2013; 14(1):547-562.

Chicago/Turabian Style

Mohammad, Mohammad G.; Hassanpour, Masoud; Tsai, Vicky W.W.; Li, Hui; Ruitenberg, Marc J.; Booth, David R.; Serrats, Jordi; Hart, Prue H.; Symonds, Geoffrey P.; Sawchenko, Paul E.; Breit, Samuel N.; Brown, David A. 2013. "Dendritic Cells and Multiple Sclerosis: Disease, Tolerance and Therapy." Int. J. Mol. Sci. 14, no. 1: 547-562.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert